Shenzhen YHLO Biotech Co (SHSE:688575) Scaled Net Operating Assets: 0.69 (As of Mar. 2026)


SHSE:688575 Shenzhen YHLO Biotech Co Ltd SHSE:688575
64 GF Score
Price ¥9.00
GF Value ¥14.56
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Shenzhen YHLO Biotech Co Scaled Net Operating Assets?

Shenzhen YHLO Biotech Co SHSE:688575 -1.21% 64 Scaled Net Operating Assets is 0.69 as of Mar. 2026. GuruFocus rates SHSE:688575 with a GF Score™ of 64/100 and a GF Value™ of ¥14.56 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Shenzhen YHLO Biotech Co's operating assets for the quarter that ended in Mar. 2026 was ¥3,639 Mil. Shenzhen YHLO Biotech Co's operating liabilities for the quarter that ended in Mar. 2026 was ¥659 Mil. Shenzhen YHLO Biotech Co's Total Assets for the quarter that ended in Dec. 2025 was ¥4,289 Mil. Therefore, Shenzhen YHLO Biotech Co's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.69.


Shenzhen YHLO Biotech Co Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Shenzhen YHLO Biotech Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen YHLO Biotech Co Scaled Net Operating Assets Chart

Shenzhen YHLO Biotech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only 0.95 0.73 0.60 0.81 0.69

Shenzhen YHLO Biotech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.70 0.72 0.72 0.70

SHSE:688575 vs ABT, SYK, MDT: Scaled Net Operating Assets Comparison

For the Medical Devices subindustry, Shenzhen YHLO Biotech Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen YHLO Biotech Co Scaled Net Operating Assets vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shenzhen YHLO Biotech Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Shenzhen YHLO Biotech Co's Scaled Net Operating Assets falls into.


SHSE:688575
64GF Score
Shenzhen YHLO Biotech Co Ltd SHSE:688575
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shenzhen YHLO Biotech Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Shenzhen YHLO Biotech Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(3765.252-705.481)/4415.093
=0.69

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=4288.73 - 523.478
=3765.252

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1601.396 - 587.892 - 308.023
=705.481

Shenzhen YHLO Biotech Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(3638.922-658.811)/4288.73
=0.69

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=4300.88 - 661.958
=3638.922

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1598.016 - 598.629 - 340.576
=658.811

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.69 mean?
Shenzhen YHLO Biotech Co (SHSE:688575) has a Scaled Net Operating Assets of 0.69 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Shenzhen YHLO Biotech Co and its competitors.
Is Shenzhen YHLO Biotech Co's Scaled Net Operating Assets too high?
Shenzhen YHLO Biotech Co's current Scaled Net Operating Assets is 0.69. Overall, Shenzhen YHLO Biotech Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen YHLO Biotech Co's Scaled Net Operating Assets compare to ABT and SYK?
Shenzhen YHLO Biotech Co's Scaled Net Operating Assets of 0.69 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Shenzhen YHLO Biotech Co and its competitors. Shenzhen YHLO Biotech Co's current Scaled Net Operating Assets is 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen YHLO Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co (SHSE:688575) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥14.56, compared to a current price of ¥9.00 — trading 38.2% below its estimated fair value. The current Scaled Net Operating Assets is 0.69. Shenzhen YHLO Biotech Co's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Shenzhen YHLO Biotech Co (SHSE:688575), the current Scaled Net Operating Assets is 0.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shenzhen YHLO Biotech Co (SHSE:688575) Overvalued in 2026?

Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co stock appears to be undervalued. The current stock price of ¥9.00 is trading 38.2% below its estimated GF Value™ of ¥14.56. GuruFocus considers Shenzhen YHLO Biotech Co to be Significantly Undervalued.

Key valuation signals for SHSE:688575:

  • Scaled Net Operating Assets: 0.69
  • GF Value™: ¥14.56 vs. price of ¥9.00 (38.2% below fair value)
  • GF Score™: 64/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shenzhen YHLO Biotech Co Business Description

Address Baolong 2nd Road, Baolong Street, Building 1, Yahuilong Biotechnology Factory Area, Longgang District, Guangdong Province, Shenzhen, CHN, 518116
Shenzhen YHLO Biotech Co Ltd is engaged in the research, development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay. Its product portfolio includes solutions based on technologies such as chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. Its products are used in diagnostic applications including autoimmunity, reproductive health, infection, liver disease, and respiratory disease testing, and are supplied to healthcare institutions and testing centers.
64GF Score

Get the complete analysis for SHSE:688575

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥9.00
Price
¥14.56
GF Value